Our latest articles
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
39% of the patients assessed carried this biomarker, the conference presentation reveals.
Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.